Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Clin Lab Sci ; 54(3): 371-377, 2024 May.
Article in English | MEDLINE | ID: mdl-39048167

ABSTRACT

Adult polycystic kidney disease (APKD) is a genetic disorder leading to premature renal dysfunction and failure. The prevalence of malignant renal tumors occurring in the APKD setting has been rarely reported. OBJECTIVE: To better characterize malignant renal tumors in nephrectomy specimens of APKD and apply modern pathologic evaluation. METHODS: We reviewed our database of APKD specimens over the past 11 years (from 2012 to 2023) for primary malignant tumors within the kidneys of APKD. RESULTS: Of 48 nephrectomy specimens with APKD evaluated, 10 malignant renal tumors were identified, indicating a prevalence of 20.8 % (10/48). These included three clear cell (cc) renal cell carcinomas (RCC) (ranging from 1 mm to 6.7 cm), three papillary RCCs (2.5, 3.5, and 14 cm with lymph node metastasis), two cases of clear cell papillary (CCP) RCC, one acquired cystic disease (ACD) with associated RCC (4 mm), and one urothelial adenocarcinoma. The urothelial adenocarcinoma was found near a tubulovillous adenoma in a collecting duct and stained positively for GATA3 and Uroplakin-2 but was negative for PAX8 & CDX2. The tumor showed extensive invasion into perirenal fatty tissue and the rectum. Next generating sequencing (NGS) analysis of the tumor showed mutations in TERT, RB1, TP53, ERBB2, and TET1 genes, further supporting its urothelial origin. CONCLUSIONS: We found a prevalence of 20.8%, which was higher than in previous reports of malignant renal tumors in patients who underwent resections for APKD. Renal tumors were mostly from damaged proximal tubular origins (clear cell or papillary RCC), but less commonly were from distal tubular or urothelial cells as well (clear cell papillary RCC and urothelial adenocarcinoma).


Subject(s)
Kidney Neoplasms , Polycystic Kidney Diseases , Humans , Kidney Neoplasms/pathology , Kidney Neoplasms/genetics , Kidney Neoplasms/epidemiology , Male , Female , Middle Aged , Aged , Polycystic Kidney Diseases/pathology , Polycystic Kidney Diseases/genetics , Adult , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/genetics , Carcinoma, Renal Cell/epidemiology , Kidney Tubules, Proximal/pathology , Nephrectomy
2.
Tissue Eng Part A ; 25(7-8): 575-587, 2019 04.
Article in English | MEDLINE | ID: mdl-30187829

ABSTRACT

IMPACT STATEMENT: This study reveals that multicellular aggregation induces metabolic reprogramming via mechanical compaction in lieu of formation of a hypoxic core. Utilizing biomechanical knowledge gained from planar culture, we set forth a novel three-dimensional (3D) model of size-dependent cortical compaction and demonstrated its role in metabolic reconfiguration. Ultimately, this study establishes mechanical compaction and its spatial gradients as key regulatory factors and design parameters in the development of 3D human adipose-derived mesenchymal stem cell aggregates.


Subject(s)
Mesenchymal Stem Cells/cytology , Stem Cells/cytology , Adipose Tissue/cytology , Adipose Tissue/metabolism , Cell Aggregation/physiology , Cell Culture Techniques/methods , Cell Differentiation/physiology , Cell Proliferation/physiology , Cells, Cultured , Fructose-Bisphosphate Aldolase/metabolism , Humans , Mesenchymal Stem Cells/metabolism , Stem Cells/metabolism
3.
Biochim Biophys Acta Mol Cell Res ; 1865(9): 1173-1186, 2018 09.
Article in English | MEDLINE | ID: mdl-29807053

ABSTRACT

Yin Yang 1 (YY1) is a multifunctional transcription factor that can activate or repress transcription depending on the promotor and/or the co-factors recruited. YY1 is phosphorylated in various signaling pathways and is critical for different biological functions including embryogenesis, apoptosis, proliferation, cell-cycle regulation and tumorigenesis. Here we report that YY1 is a substrate for c-Abl kinase phosphorylation at conserved residue Y254 in the spacer region. Pharmacological inhibition of c-Abl kinase by imatinib, nilotinib and GZD824, knock-down of c-Abl using siRNA, and the use of c-Abl kinase-dead drastically reduces tyrosine phosphorylation of YY1. Both radioactive and non-radioactive in vitro kinase assays, as well as co-immunoprecipitation in different cell lines, show that the target of c-Abl phosphorylation is tyrosine residue 254. c-Abl phosphorylation has little effect on YY1 DNA binding ability or cellular localization in asynchronous cells. However, functional studies reveal that c-Abl mediated phosphorylation of YY1 regulates YY1's transcriptional ability in vivo. In conclusion, we demonstrate the novel role of c-Abl kinase in regulation of YY1's transcriptional activity, linking YY1 regulation with c-Abl tyrosine kinase signaling pathways.


Subject(s)
Oncogene Proteins v-abl/metabolism , Transcription, Genetic , YY1 Transcription Factor/chemistry , YY1 Transcription Factor/metabolism , Benzamides/pharmacology , Conserved Sequence , Gene Knockout Techniques , Gene Silencing , HCT116 Cells , HEK293 Cells , HeLa Cells , Humans , Imatinib Mesylate/pharmacology , MCF-7 Cells , Oncogene Proteins v-abl/genetics , Phosphorylation , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Tyrosine/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...